

# Special Issue

## Multitarget Ligands

### Message from the Guest Editors

There are several disorders that cannot be properly treated with the old “*one target-one molecule*” approach, due to their multifactorial character. The complexity of these diseases suggests exploiting the simultaneous modulation of more than one target, a concept known also as polypharmacology, by using compounds which are able to interact with different macromolecules involved in the disorder under investigation. Even if the success of several drugs can be due to their fortuitous interaction with multiple macromolecules, historically, the design of multitarget-directed ligands was developed to treat Alzheimer’s Disease. Later, this approach was extended to different therapeutic areas, among them cancer, inflammation, pain, and infectious diseases. This Special Issue aims to collect research papers and short communication to provide an overview on the recent advances in the design, synthesis, and biological evaluation of multitarget ligands for innovative therapeutic treatments.

### Guest Editors

Prof. Dr. Maria Novella Romanelli


Department of Neuroscience, Psychology, Drug Research and Child’s Health, Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, Via Ugo Schiff 6, 50019 Sesto Fiorentino, Italy

Prof. Dr. Silvia Dei

Department of Neuroscience, Psychology, Drug Research and Child’s Health, Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, Via Ugo Schiff 6, 50019 Sesto Fiorentino, Italy

### Deadline for manuscript submissions

closed (30 September 2020)



## Molecules

an Open Access Journal  
by MDPI

Impact Factor 4.6  
CiteScore 8.6  
Indexed in PubMed




[mdpi.com/si/28814](https://mdpi.com/si/28814)

*Molecules*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[molecules@mdpi.com](mailto:molecules@mdpi.com)

[mdpi.com/journal/  
molecules](https://mdpi.com/journal/molecules)





# Molecules

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.6  
CiteScore 8.6  
Indexed in PubMed



[mdpi.com/journal/  
molecules](https://mdpi.com/journal/molecules)



## About the Journal

### Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

---

### Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

#### Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).